ALNYLAM PHARMACEUTICALS, INC. Property, Plant and Equipment
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Property, Plant and Equipment of $554.14 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentNet · last filed 2026-07-30
- 2026-06-30: Property, Plant and Equipment, Net $554.14M.
- 2025-12-31: Property, Plant and Equipment, Net $513.15M.
- 2025-09-30: Property, Plant and Equipment, Net $501.75M.
- 2025-06-30: Property, Plant and Equipment, Net $499.79M.
| Period end | Property, Plant and Equipment, Net |
|---|---|
| 2026-06-30 | $554.14M 10-Q · filed 2026-07-30 |
| 2025-12-31 | $513.15M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $501.75M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $499.79M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $498.68M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $502.78M 10-K · filed 2026-02-12 |
| 2024-09-30 | $507.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $517.16M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $523.46M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $526.06M 10-K · filed 2025-02-13 |
| 2023-09-30 | $525.59M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $527.47M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $523.03M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $523.49M 10-K · filed 2024-02-15 |
| 2022-09-30 | $514.82M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $508.20M 10-Q · filed 2022-07-28 |
| 2022-03-31 | $504.39M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $501.96M 10-K · filed 2023-02-23 |
| 2021-09-30 | $484.94M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $470.70M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $464.57M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $465.03M 10-K · filed 2022-02-10 |
| 2020-09-30 | $444.69M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $439.13M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $429.81M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $425.18M 10-K · filed 2021-02-11 |
| 2019-09-30 | $396.46M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $371.77M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $341.71M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $320.66M 10-K · filed 2020-02-13 |
| 2018-09-30 | $272.65M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $227.84M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $201.98M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $181.90M 10-K · filed 2019-02-14 |
| 2017-09-30 | $161.90M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $147.53M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $129.96M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $114.57M 10-K · filed 2018-02-15 |
| 2016-09-30 | $74.22M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $55.39M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $36.81M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $27.81M 10-K · filed 2017-02-15 |
| 2015-09-30 | $26.32M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $25.17M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $21.17M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $21.74M 10-K · filed 2016-02-12 |
| 2014-09-30 | $18.81M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $16.95M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $15.73M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $16.45M 10-K · filed 2015-02-13 |
| 2013-09-30 | $16.97M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $18.05M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $18.98M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $19.80M 10-K · filed 2014-02-20 |
| 2012-09-30 | $18.79M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $14.21M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $13.70M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $14.64M 10-K · filed 2013-02-19 |
| 2011-09-30 | $15.31M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $16.25M 10-Q · filed 2011-08-03 |
| 2011-03-31 | $17.02M 10-Q · filed 2011-05-05 |
| 2010-12-31 | $18.29M 10-K · filed 2012-02-13 |
| 2010-09-30 | $18.40M 10-Q · filed 2010-11-04 |
| 2010-06-30 | $18.55M 10-Q · filed 2010-08-05 |
| 2009-12-31 | $18.32M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |